Liver Cancer and Immunotherapy in the Liquid Biopsy Era

The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy. The main questions it aims to answer are: * Is multi-omic liquid biopsy approach able to identify a strong predictive biomarker of immunotherapy efficiency? * Is there a correlation between tissue biopsy (PD-L1 tissue level of expression) and liquid biopsy (detection of CTC expressing PD-L1) in HCC patients? Participants blood will be collected at several time points.

Trial Details

NCT ID
NCT05810402
Phase
NA
Sponsor
University Hospital, Montpellier
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Liquid Biopsy
Locations (sample)
  • Montpellier, France|43.61093,3.87635

Key Eligibility Criteria

  • Patients of at least 18 years old,
  • Patients with advanced hepatocellular carcinoma or HCC with indication for first-line PD-1 or PD-L1 immunotherapy in MDT, without prior systemic th…
  • The diagnosis of HCC is established according to imaging criteria (LI-RADSv2018 criteria) or after histological evidence,
  • Advanced HCC defined by BCLC stages B and C,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →